Udvardy M, Rák K
Debreceni Orvostudományi Egyetem, II. Belgyógyászati Klinika.
Orv Hetil. 1997 Jan 12;138(2):59-65.
The past decades have exposed and faced antithrombotic therapy (anticoagulants, antiplatelet agents, and fibrinolytics) to new challenges. The reperfusion treatment modalities of myocardial infarction needed improvement of fibrinolytic agents and adjuvant anticoagulant-antiplatelet therapy. The secondary prevention of stroke, along with the renewal of thrombolytic and anticoagulant therapy seems to be an other major area of new approach to antithrombotic therapy. The reocclusion and restenosis of coronary arteries means the most difficult issue and task for antithrombotic treatment modalities. These requirements accelerated the development of novel antithrombotic agents, the disintegrin family, the monoclonals directed against platelet adhesion and aggregation, the application of hirudin and its analogs and new generation of thrombolytic agents. Combined and sequential administration of different antithrombotic agents receives growing attention and seems also to be promising.
在过去几十年中，抗血栓治疗（抗凝剂、抗血小板药物和纤溶药物）面临着新的挑战。心肌梗死的再灌注治疗方式需要改进纤溶药物以及辅助抗凝-抗血小板治疗。中风的二级预防，连同溶栓和抗凝治疗的更新，似乎是抗血栓治疗新方法的另一个主要领域。冠状动脉的再闭塞和再狭窄是抗血栓治疗方式最困难的问题和任务。这些需求加速了新型抗血栓药物的研发，如整合素家族、针对血小板黏附和聚集的单克隆抗体、水蛭素及其类似物的应用以及新一代溶栓药物。不同抗血栓药物的联合和序贯给药越来越受到关注，而且似乎也很有前景。
